{"nctId":"NCT02576717","briefTitle":"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","startDateStruct":{"date":"2015-10-16","type":"ACTUAL"},"conditions":["Multiple Sclerosis"],"count":2494,"armGroups":[{"label":"1 mg RPC1063 (Ozanimod) oral capsule","type":"EXPERIMENTAL","interventionNames":["Drug: RPC1063"]}],"interventions":[{"name":"RPC1063","otherNames":["Ozanimod"]}],"eligibilityModule":{"eligibilityCriteria":"Eligibility Criteria:\n\nTo be eligible to participate in this trial, patients must meet all of the following criteria:\n\n1. Completed one of the parent trials\n2. Does not have a condition that would require withdrawal from one of the parent trials\n3. Has no conditions requiring treatment with a prohibited concomitant medication\n4. Is not receiving treatment with any of the following drugs or interventions within the corresponding timeframe:\n\n   At Baseline (Day 1)\n   * CYP2C8 inhibitors (eg, gemfibrozil or clopidogrel) or inducers (eg, rifampicin) Two weeks prior to Baseline (Day 1)\n   * Monoamine oxidase inhibitors (eg, selegiline, phenelzine)\n5. Ability to provide written informed consent and to be compliant with the schedule of protocol assessments\n6. Female patients of childbearing potential:\n\nMust agree to practice a highly effective method of contraception throughout the study until completion of the 90-day Safety Follow-up Visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly.\n\nAcceptable methods of birth control in this study are the following:\n\n* Combined hormonal (estrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal\n* Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable\n* Placement of an intrauterine device (IUD)\n* Placement of an intrauterine hormone-releasing system (IUS)\n* Bilateral tubal occlusion\n* Vasectomised partner\n* Sexual abstinence.\n\nExclusion Criteria:","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"668","spread":null},{"groupId":"OG001","value":"775","spread":null},{"groupId":"OG002","value":"776","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Serious Adverse Events (SAEs)","description":"A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"134","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation","description":"An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events (AEs) Leading to Withdrawal","description":"An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events (AEs) of Special Interest","description":"An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Abnormalities in Blood Absolute Lymphocyte Count (ALC)","description":"An absolute lymphocyte count (ALC) is a part of a blood test that measures the number of lymphocytes, a type of white blood cell, in the blood. Lymphocytes help fight infections and diseases. Reductions in ALC levels for participants in this study is expected and is a primary pharmacodynamic effect of RPC1063.\n\nLLN = Lower limit of normal","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"323","spread":null},{"groupId":"OG002","value":"339","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"497","spread":null},{"groupId":"OG001","value":"620","spread":null},{"groupId":"OG002","value":"616","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"592","spread":null},{"groupId":"OG001","value":"703","spread":null},{"groupId":"OG002","value":"704","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Abnormalities in White Blood Cell Count (WBC)","description":"A white blood cell count is a part of a blood test that measures the number of white blood cells in the blood. White blood cells help fight infections and diseases.\n\nLLN = Lower limit of normal","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Abnormalities in Blood Absolute Neutrophil Count (ANC)","description":"An absolute neutrophil count is a part of a blood test that measures the number of neutrophils, a type of white blood cell, in the blood. Neutrophils help fight infections and diseases.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Abnormalities in Specific Liver Function Tests","description":"The number of participants with laboratory abnormalities in specific liver tests above ULN by category. ULN = Upper Limit of Normal","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"311","spread":null},{"groupId":"OG001","value":"353","spread":null},{"groupId":"OG002","value":"353","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Electrocardiogram (ECG) Result Abnormalities","description":"An electrocardiogram (ECG) measures electrical activity of the heart to detect cardiac problems.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"186","spread":null},{"groupId":"OG002","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"215","spread":null},{"groupId":"OG002","value":"205","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Clinically Relevant Abnormalities in Vital Signs","description":"Vital signs included body temperature, sitting heart rate/pulse (HR), sitting systolic blood pressure (SBP), sitting diastolic blood pressure (DBP).\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Physical Examination Abnormalities","description":"The number of participants with abnormal physical examination results. The assessments included abdominal, extremity, head, heart, lungs, neck, neurological non-MS, other and skin assessments.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Self-Identifying Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The Columbia-Suicide Severity Rating Scale (C-SSRS) is a unique suicide risk assessment tool that supports suicide risk assessment through a series of simple, plain-language questions. The answers help users identify whether someone is at risk for suicide, assess the severity and immediacy of that risk, and gauge the level of support that the person needs.\n\nResults are displayed as the number of participants who answered \"Yes\" to at least one of the 10 questions in the suicidal ideation or suicidal behavior section.\n\nIdeation from 1 (wishing to be dead) - 5 (Active suicidal ideation with specific plan and intent) Behavior from 6 (Preparatory acts or behavior) - 10 (Completed suicide). Baseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Changes in Suicidality From Last Day on Treatment Per the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The Columbia-Suicide Severity Rating Scale (C-SSRS) is a unique suicide risk assessment tool that supports suicide risk assessment through a series of simple, plain-language questions. The answers help users identify whether someone is at risk for suicide, assess the severity and immediacy of that risk, and gauge the level of support that the person needs.\n\nResults are displayed as the number of participants who answered \"Yes\" to at least one of the 10 questions in the suicidal ideation or suicidal behavior section.\n\nIdeation from 1 (wishing to be dead) - 5 (Active suicidal ideation with specific plan and intent) Behavior from 6 (Preparatory acts or behavior) - 10 (Completed suicide).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Physician's Withdrawal Checklist (PWC-20) Total Score From Last Day on Treatment","description":"The PWC-20 is a rater-administered 20-item scale to assess signs and symptoms of withdrawal. Twenty items are rated on a 4-point scale as not present (0 points), mild (1 point), moderate (2 points), or severe (3 points). The points from all items are calculated as a total score. Higher scores indicate more severe withdrawal symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"6.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"5.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"4.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"4.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"4.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"5.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"5.15"}]}]}]},{"type":"PRIMARY","title":"Change in Hospital Anxiety and Depression Scale (HADS) Score From Last Day on Treatment","description":"The HADS is a validated patient reported outcome for assessing anxiety and depression. It consists of 14 items in total, 7 items related to anxiety and 7 items related to depression. For each item patients select a statement (valued at 0 to 3 points) that closest matches their own feeling over the past week. Separate total scores for anxiety and depression are derived by adding up points. Total scores can range from 0 to 21 points. Higher scores indicate more severe anxiety and depression and scores of 8 to 10 are generally considered indicative of borderline anxiety/depression disorders and scores of 11 and higher are generally considered indicative of anxiety/depression disorders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"3.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.99"}]}]}]},{"type":"PRIMARY","title":"Changes in Epworth Sleepiness Scale (ESS) Score From Last Day on Treatment","description":"The ESS is a validated self administered questionnaire with 8 questions. Respondents rate on a 4-point scale (0 to 3) their chances of dozing off or falling asleep while engaged in 8 different activities. The ESS score is the sum of 8 item scores and can range from 0 to 24 points. Higher scores indicate more daytime sleepiness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"4.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"4.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"4.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"4.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"4.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"4.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"3.75"}]}]}]},{"type":"PRIMARY","title":"Changes in Vital Sign Values From Last Day on Treatment","description":"Vital signs included sitting systolic blood pressure (SBP), sitting diastolic blood pressure (DBP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.77","spread":"11.189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"8.311"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"8.931"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"7.911"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"8.128"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"9.029"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"11.135"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"10.865"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":"8.356"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"8.218"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"7.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.80","spread":"7.275"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.82","spread":"7.643"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"8.181"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"8.103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.01","spread":"7.689"}]}]}]},{"type":"SECONDARY","title":"Annualized Relapse Rate (ARR)","description":"The Annualized Relapse Rate (ARR) is the average number of relapses per study arm in one year. A relapse is defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by a relatively stable or improving neurological state of at least 30 days. The adjusted ARR was based on the negative binomial regression model with parent treatment group, adjusted for region (Eastern Europe vs Rest of World), age at parent baseline, and the parent baseline number of gadolinium-enhanced (GdE) lesions. The natural log transformation of time on treatment was used as an offset term to adjust for participants having different exposure times.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.097","spread":null},{"groupId":"OG001","value":"0.108","spread":null},{"groupId":"OG002","value":"0.090","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Relapse (TFR)","description":"The time between first dose of study treatment and first relapse if experienced by a participant. A participant was censored if follow-up ended before a relapse occurred, whether due to the participant completing study, withdrawing from the study, or due to the cutoff of data collection for the analysis. The censor date was the date of the end of study or the date of the data cutoff for participant who were ongoing. Participants who withdrew from the study after the baseline visit were censored at the last known date while on study. Based on Kaplan-Meier product limit estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Were Relapse Free","description":"The number of participants who did not experience relapse. A relapse is defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by a relatively stable or improving neurological state of at least 30 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"513","spread":null},{"groupId":"OG001","value":"605","spread":null},{"groupId":"OG002","value":"605","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions Per Scan at Each Visit","description":"Adjusted Mean of new enlarging T2 lesions per scan at each visit. Based on a negative binomial regression model, adjusted for parent study, region (Eastern Europe vs. Rest of the World), age at Baseline, and baseline number of GdE lesions.\n\nT2 Magnetic Resonance Imaging (MRI) sequences are used to highlight areas of demyelination in brain neurons, which happens when the outer layer of the neurons is damaged due to multiple sclerosis (MS) activity. T2 sequences can be used to count the total number of MS lesions, which look like bright white spots on T2 sequences, and can be called \"hyperintense\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.532","spread":null},{"groupId":"OG001","value":"1.163","spread":null},{"groupId":"OG002","value":"1.302","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.254","spread":null},{"groupId":"OG001","value":"1.005","spread":null},{"groupId":"OG002","value":"1.190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.136","spread":null},{"groupId":"OG001","value":"1.021","spread":null},{"groupId":"OG002","value":"1.142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.935","spread":null},{"groupId":"OG001","value":"0.915","spread":null},{"groupId":"OG002","value":"1.044","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.791","spread":null},{"groupId":"OG001","value":"0.864","spread":null},{"groupId":"OG002","value":"0.935","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.800","spread":null},{"groupId":"OG001","value":"0.780","spread":null},{"groupId":"OG002","value":"0.926","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Number of Gadolinium-Enhanced (GdE) Brain MRI Lesions Per Scan at Each Visit","description":"Number of gadolinium-enhanced (GdE) (also called GdE enhanced T1) brain MRI lesions per scan at each visit.\n\nIncreased numbers of GdE lesions indicates an increase in the in the amount of active inflammation at the site and may be indicative of progressive disease.\n\nBased on a negative binomial regression model, adjusted for parent study, region (Eastern Europe vs. Rest of the World), age at Baseline, and Baseline number of GdE lesions.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.460","spread":null},{"groupId":"OG001","value":"0.244","spread":null},{"groupId":"OG002","value":"0.177","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.106","spread":null},{"groupId":"OG001","value":"0.130","spread":null},{"groupId":"OG002","value":"0.205","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.138","spread":null},{"groupId":"OG001","value":"0.149","spread":null},{"groupId":"OG002","value":"0.224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.194","spread":null},{"groupId":"OG001","value":"0.155","spread":null},{"groupId":"OG002","value":"0.243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.230","spread":null},{"groupId":"OG001","value":"0.161","spread":null},{"groupId":"OG002","value":"0.245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.074","spread":null},{"groupId":"OG001","value":"0.062","spread":null},{"groupId":"OG002","value":"0.076","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.099","spread":null},{"groupId":"OG001","value":"0.102","spread":null},{"groupId":"OG002","value":"0.082","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Disability Progression as Defined by a Sustained Worsening in Expanded Disability Status Scale (EDSS)","description":"Multiple sclerosis (MS) disability progression is defined as a sustained worsening in EDSS of 1.0 points or more from baseline, confirmed after a 3-month and 6-month period. The EDSS is a standardized method, widely accepted, numerical scale used to evaluate disability in people with multiple sclerosis (MS). The EDSS is evaluated according to signs and symptoms observed during a standard neurological examination. These clinical observations are classified in 7 FS scales, each of them grading signs and symptoms for different neurological functions: pyramidal, cerebellar, brainstem, sensory, bowel or bladder, visual, and cerebral.\n\nDerived using Kaplan-Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Free of Gadolinium-Enhanced (GdE) Brain Lesions at Each Visit","description":"Number of participants without gadolinium enhanced (GdE) brain MRI lesions at each visit. Increased numbers of GdE lesions indicates an increase in the in the amount of active inflammation at the site and may be indicative of progressive disease.\n\nBased on cumulative number of GdE lesions at a participant level.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"538","spread":null},{"groupId":"OG001","value":"609","spread":null},{"groupId":"OG002","value":"662","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"622","spread":null},{"groupId":"OG001","value":"644","spread":null},{"groupId":"OG002","value":"627","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"582","spread":null},{"groupId":"OG001","value":"601","spread":null},{"groupId":"OG002","value":"596","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"538","spread":null},{"groupId":"OG001","value":"576","spread":null},{"groupId":"OG002","value":"569","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"506","spread":null},{"groupId":"OG001","value":"518","spread":null},{"groupId":"OG002","value":"517","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"478","spread":null},{"groupId":"OG001","value":"528","spread":null},{"groupId":"OG002","value":"512","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"149","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Free of New or Enlarging T2 Lesions at Each Visit","description":"Number of participants without new or enlarging T2 brain MRI lesions at each visit. Some multiple Sclerosis (MS) lesions appear as bright spots in a T2-weighted MRI scan - these are called T2 lesions. The presence of new or larger T2 lesions may mean the participant is at higher risk of disability and may have a less favorable long-term outcome.\n\nBased on cumulative number of new or enlarging T2 lesions at a participant level.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"322","spread":null},{"groupId":"OG001","value":"400","spread":null},{"groupId":"OG002","value":"419","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"260","spread":null},{"groupId":"OG001","value":"323","spread":null},{"groupId":"OG002","value":"338","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220","spread":null},{"groupId":"OG001","value":"264","spread":null},{"groupId":"OG002","value":"271","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"223","spread":null},{"groupId":"OG002","value":"223","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"213","spread":null},{"groupId":"OG002","value":"209","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Normalized Brain Volume (Atrophy) on Brain MRI Scans From Baseline at Each Visit","description":"Percent change in normalized brain volume (Atrophy) on brain MRI scans from baseline at each visit. Brain atrophy can be seen in the earliest stages of multiple sclerosis (MS) and is a reliable predictor of future physical and cognitive disability.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.407","spread":"0.731"},{"groupId":"OG001","value":"-0.359","spread":"0.607"},{"groupId":"OG002","value":"-0.385","spread":"0.602"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.702","spread":"0.809"},{"groupId":"OG001","value":"-0.657","spread":"0.713"},{"groupId":"OG002","value":"-0.671","spread":"0.706"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.992","spread":"0.882"},{"groupId":"OG001","value":"-0.947","spread":"0.825"},{"groupId":"OG002","value":"-0.977","spread":"0.764"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.241","spread":"1.012"},{"groupId":"OG001","value":"-1.214","spread":"0.980"},{"groupId":"OG002","value":"-1.233","spread":"0.949"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.485","spread":"1.079"},{"groupId":"OG001","value":"-1.478","spread":"1.014"},{"groupId":"OG002","value":"-1.544","spread":"1.017"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.889","spread":"1.288"},{"groupId":"OG001","value":"-1.696","spread":"1.118"},{"groupId":"OG002","value":"-1.922","spread":"1.290"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.283","spread":"1.206"},{"groupId":"OG001","value":"-1.298","spread":"1.133"},{"groupId":"OG002","value":"-1.355","spread":"1.121"}]}]}]},{"type":"SECONDARY","title":"Change in Multiple Sclerosis Functional Composite (MSFC) Score From Baseline at Each Applicable Visit","description":"The Multiple Sclerosis Functional Composite (MSFC) is a 3-part tool to measure disability progression in those with multiple sclerosis (MS). It assesses leg, arm, hand, and cognitive function using 3 individual scales: - The Timed 25-Foot Walk: To measure leg function - The 9-Hole Peg Test: To measure arm and hand function - The Symbol Digit Modalities Test (SDMT): To measure cognitive processing speed, flexibility, and calculation ability. Scores from each of the three are converted into Z-scores and averaged to create an overall composite score. The Low-Contrast Letter Acuity Test (LCLA) is performed with the MSFC using a set of charts to assess low contrast visual acuity. Each chart corresponds to a different contrast level, and charts are scored based on the number of letters identified correctly. A Z-score of 0 represents the population mean. Standard deviations above the mean represent a better outcome. Baseline refers to assessments on or before receiving study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.058","spread":"2.540"},{"groupId":"OG001","value":"-0.085","spread":"0.488"},{"groupId":"OG002","value":"-0.064","spread":"0.618"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.072","spread":"0.855"},{"groupId":"OG001","value":"-0.082","spread":"0.615"},{"groupId":"OG002","value":"-0.086","spread":"0.632"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.105","spread":"0.876"},{"groupId":"OG001","value":"-0.100","spread":"0.529"},{"groupId":"OG002","value":"-0.109","spread":"0.656"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.162","spread":"1.025"},{"groupId":"OG001","value":"-0.148","spread":"0.611"},{"groupId":"OG002","value":"-0.103","spread":"1.460"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.182","spread":"1.062"},{"groupId":"OG001","value":"-0.174","spread":"0.675"},{"groupId":"OG002","value":"-0.148","spread":"0.580"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.248","spread":"1.256"},{"groupId":"OG001","value":"-0.239","spread":"0.745"},{"groupId":"OG002","value":"-0.219","spread":"0.672"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.099","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.043","spread":"1.919"},{"groupId":"OG001","value":"-0.059","spread":"0.402"},{"groupId":"OG002","value":"-0.055","spread":"0.483"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.056","spread":"0.655"},{"groupId":"OG001","value":"-0.064","spread":"0.483"},{"groupId":"OG002","value":"-0.074","spread":"0.509"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.097","spread":"0.686"},{"groupId":"OG001","value":"-0.089","spread":"0.447"},{"groupId":"OG002","value":"-0.103","spread":"0.542"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.158","spread":"0.796"},{"groupId":"OG001","value":"-0.149","spread":"0.525"},{"groupId":"OG002","value":"-0.103","spread":"1.125"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.175","spread":"0.837"},{"groupId":"OG001","value":"-0.181","spread":"0.572"},{"groupId":"OG002","value":"-0.153","spread":"0.505"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.237","spread":"0.983"},{"groupId":"OG001","value":"-0.250","spread":"0.624"},{"groupId":"OG002","value":"-0.213","spread":"0.590"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.103","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change in Multiple Sclerosis Quality of Life 54 Score From Baseline at Each Applicable Visit","description":"The Multiple Sclerosis Quality of Life 54 (MSQOL-54) questionnaire is a health-related quality of life (HRQOL) instrument specific for multiple sclerosis (MS). This 54-item instrument generates 12 subscales along with two summary scores (physical health and mental health - derived from a weighted combination of scale scores), and two additional single-item measures. The subscales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The MSQOL-54 items are transformed to 0-100 scores, and final scores are obtained by averaging items within the scales. The overall quality of life is assessed in question 54, which is scored on a scale of 0-100. Higher scores indicate better health-related quality of life. Baseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"10.68"},{"groupId":"OG001","value":"-0.1","spread":"10.55"},{"groupId":"OG002","value":"0.2","spread":"9.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"11.51"},{"groupId":"OG001","value":"-0.6","spread":"10.76"},{"groupId":"OG002","value":"-0.3","spread":"11.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"12.20"},{"groupId":"OG001","value":"-0.6","spread":"11.23"},{"groupId":"OG002","value":"-0.4","spread":"12.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"12.60"},{"groupId":"OG001","value":"-1.4","spread":"12.66"},{"groupId":"OG002","value":"-1.4","spread":"12.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"13.27"},{"groupId":"OG001","value":"-2.7","spread":"13.11"},{"groupId":"OG002","value":"-2.1","spread":"12.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"14.97"},{"groupId":"OG001","value":"-3.0","spread":"13.42"},{"groupId":"OG002","value":"-3.0","spread":"13.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.3","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Volume of Gadolinium Enhanced T1 Lesions","description":"Change from baseline in volume of gadolinium enhanced T1 lesions. T1-lesions are permanently damaged areas of the brain that appear as dark spots or \"black holes\" on a type of MRI scan. The growth of T1 lesions may mean the participant's Multiple Sclerosis (MS) is progressing.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.092","spread":"0.435"},{"groupId":"OG001","value":"-0.015","spread":"0.229"},{"groupId":"OG002","value":"-0.004","spread":"0.180"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.099","spread":"0.431"},{"groupId":"OG001","value":"-0.017","spread":"0.193"},{"groupId":"OG002","value":"0.009","spread":"0.264"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.089","spread":"0.485"},{"groupId":"OG001","value":"-0.018","spread":"0.183"},{"groupId":"OG002","value":"0.012","spread":"0.237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.081","spread":"0.467"},{"groupId":"OG001","value":"-0.012","spread":"0.204"},{"groupId":"OG002","value":"0.017","spread":"0.252"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.090","spread":"0.448"},{"groupId":"OG001","value":"-0.017","spread":"0.217"},{"groupId":"OG002","value":"0.000","spread":"0.189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.044","spread":"0.145"},{"groupId":"OG001","value":"0.003","spread":"0.157"},{"groupId":"OG002","value":"0.014","spread":"0.307"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Volume of T2 Lesions","description":"Some multiple Sclerosis (MS) lesions appear as bright spots in a T2-weighted MRI scan - these are called T2 lesions. Larger T2 lesions may mean the participant is at higher risk of disability and may have a less favorable long-term outcome.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.190","spread":"1.498"},{"groupId":"OG001","value":"0.174","spread":"1.154"},{"groupId":"OG002","value":"0.278","spread":"1.384"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.307","spread":"1.633"},{"groupId":"OG001","value":"0.303","spread":"1.503"},{"groupId":"OG002","value":"0.518","spread":"2.294"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.536","spread":"2.218"},{"groupId":"OG001","value":"0.456","spread":"1.597"},{"groupId":"OG002","value":"0.711","spread":"2.540"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.695","spread":"2.805"},{"groupId":"OG001","value":"0.583","spread":"1.975"},{"groupId":"OG002","value":"0.952","spread":"2.945"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.709","spread":"2.907"},{"groupId":"OG001","value":"0.683","spread":"2.470"},{"groupId":"OG002","value":"0.987","spread":"3.197"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.889","spread":"2.760"},{"groupId":"OG001","value":"0.557","spread":"2.465"},{"groupId":"OG002","value":"1.234","spread":"4.307"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Volume of Unenhancing T1 Lesions","description":"Change from baseline in volume of unenhancing T1 lesions. T1-lesions are permanently damaged areas of the brain that appear as dark spots or \"black holes\" on a type of MRI scan. The growth of T1 lesions may mean the participant's Multiple Sclerosis (MS) is progressing.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.625","spread":"2.012"},{"groupId":"OG001","value":"-0.772","spread":"1.792"},{"groupId":"OG002","value":"-0.760","spread":"1.869"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.192","spread":"1.837"},{"groupId":"OG001","value":"-0.465","spread":"1.735"},{"groupId":"OG002","value":"-0.455","spread":"1.758"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.482","spread":"2.913"},{"groupId":"OG001","value":"-0.618","spread":"2.430"},{"groupId":"OG002","value":"-0.583","spread":"2.249"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.398","spread":"3.025"},{"groupId":"OG001","value":"-0.423","spread":"2.439"},{"groupId":"OG002","value":"-0.403","spread":"2.171"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.261","spread":"2.885"},{"groupId":"OG001","value":"-0.356","spread":"2.679"},{"groupId":"OG002","value":"-0.209","spread":"2.134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.047","spread":"2.209"},{"groupId":"OG001","value":"-0.372","spread":"3.257"},{"groupId":"OG002","value":"-0.256","spread":"2.036"}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of New Unenhancing T1 Lesions","description":"Number of new unenhancing T1 lesions. T1-lesions are permanently damaged areas of the brain that appear as dark spots or \"black holes\" on a type of MRI scan. The appearance of new T1 lesions may mean the participant's MS is progressing.\n\nDerived as the cumulative number of new or enlarging T1 lesions relative to baseline at a participant level.\n\nBaseline refers to assessments made on or before the first day participants received study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"4.66"},{"groupId":"OG001","value":"1.1","spread":"2.86"},{"groupId":"OG002","value":"1.2","spread":"3.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"6.30"},{"groupId":"OG001","value":"1.8","spread":"5.04"},{"groupId":"OG002","value":"2.2","spread":"5.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"8.41"},{"groupId":"OG001","value":"2.5","spread":"7.04"},{"groupId":"OG002","value":"3.0","spread":"7.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"11.02"},{"groupId":"OG001","value":"3.3","spread":"8.67"},{"groupId":"OG002","value":"4.3","spread":"10.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"11.43"},{"groupId":"OG001","value":"3.9","spread":"10.18"},{"groupId":"OG002","value":"4.9","spread":"12.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"10.11"},{"groupId":"OG001","value":"3.2","spread":"8.76"},{"groupId":"OG002","value":"5.8","spread":"16.55"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":37},"commonTop":["Nasopharyngitis","Headache","COVID-19","Upper respiratory tract infection","Lymphopenia"]}}}